Buy Baeocystin Cas 21420-58-6

Buy Baeocystin Cas 21420-58-6

Baeocystin, also known as norpsilocybin or 4-phosphoryloxy-N-methyltryptamine (4-PO-NMT), is a zwitterionic alkaloid of the tryptamine family and an analogue of psilocybin (4-PO-DMT). It is found as a minor compound in most psilocybin mushrooms together with psilocybin, psilocin (4-HO-DMT), norbaeocystin (4-PO-T), and aeruginascin (4-PO-TMT).^[1] The compound is the N–demethylated derivative of psilocybin and the 4-phosphorylated derivative of norpsilocin (4-HO-NMT).

Chemist and mycologist Jochen Gartz reported in the 1990s that baeocystin is active as a psychedelic in humans.^{[2][3][4][5][6][7]} He has stated that 4 mg produced a “threshold” or “gentle hallucinogenic experience” with “mild hallucinations for three hours” and that “10 mg of baeocystin [was] found to be about as psychoactive as a similar amount of psilocybin”.^{[2][3][4][5][6]} Gartz also personally communicated these findings to Jonathan Ott, who has reproduced the claims.^[5][6][7] Hamilton Morris has expressed surprise and skepticism about the reported psychoactivity of baeocystin however.^[7]

Gartz has also claimed that mushrooms with high baeocystin content, such as Psilocybe semilanceata, are more frequently associated with dysphoric experiences.^[8][9] Conversely, he has claimed that accidental ingestion of Inocybe aeruginascens, which contains high levels of both aeruginascin (4-PO-TMT) and baeocystin, is usually associated with euphoric experiences, in contrast to the dysphoric experiences that can occur with mushrooms containing only high levels of psilocybin.^[8][9] However, more research is needed on the effects of baeocystin and aeruginascin in humans.^[8][9]

In contrast to Gartz, mycologist Paul Stamets has reported that he tried 10 mg pure baeocystin and that it didn’t produce hallucinogenic effects, but did produce pupil dilation and apparent anxiolysis.^[10][11][12]

Baeocystin is thought to be a prodrug of norpsilocin, analogously to how psilocybin is a prodrug of psilocin.^[13] Norpsilocin is a potent and centrally penetrant agonist of the serotonin 5-HT_2A receptor and also interacts with other serotonin receptors.^[13]

Baeocystin and norpsilocin have been found to be inactive in terms of hallucinogen-like effects in rodents in multiple studies published in the 2020s.^[14][15][13] More specifically, they were unable to produce the head-twitch response (HTR), a well-established behavioral proxy of psychedelic effects, and this was in contrast to psilocybin.^[14][15][13] In one of the papers, the researchers concluded that “…baeocystin alone would likely not induce hallucinogenic effects in vivo“.^[14] As with baeocystin and norpsilocin, norbaeocystin, aeruginascin, 4-hydroxytryptamine (4-HT), and 4-HO-TMT also all failed to induce the HTR in rodents.^[14][15][13] However, these compounds have not necessarily been inactive in terms of behavioral effects in general.^[15][13]

The reasons for the apparently non-hallucinogenic nature of norpsilocin, baeocystin, and related compounds in animals (and possibly in humans), in spite of norpsilocin and others being potent serotonin 5-HT_2A receptor agonists and producing other centrally mediated behavioral effects in animals, remain unknown.^[13][15] One possibility however is that these compounds may be biased agonists of the serotonin 5-HT_2A receptor and may not sufficiently activate the intracellular signaling cascades responsible for psychedelic effects.^[13][15] On the other hand, a 2025 animal study found that both baeocystin and norpsilocin are peripherally selective with very limited ability to cross the blood–brain barrier.^[16]

Analogues of baeocystin include 4-HO-NMT, norbaeocystin (4-PO-T), psilocybin (4-PO-DMT), psilocin (4-HO-DMT), ethocybin (4-PO-DET), and aeruginascin (4-PO-TMT), among others.

Baeocystin was first isolated from the mushroom Psilocybe baeocystis,^[17] and later from P. semilanceata,^[18] Panaeolus renenosus, Panaeolus subbalteatus, and Copelandia chlorocystis.^[19]

Baeocystin was first synthesized by Troxler and colleagues in 1959.^[20]

Baeocystin is being evaluated by Pilz Bioscience (“pilz” being German for “mushroom”) under the developmental code name PLZ-1019 for the possible treatment of pervasive developmental disorders like autism in children.^[21]